Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

py.  The study will assess the safety and tolerability of ibrutinib as well as progression-free survival. This study is sponsored by the Dana-Farber Cancer Institute and completed enrollment of 63 patients.

MM

  • PCYC-1111: Phase II study of ibrutinib in patients with R/R multiple myeloma (MM). This is a Phase II, multi-center, open-label trial designed to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in patients with R/R MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone and 840 mg in combination with dexamethasone and 840 mg as a single agent. Pharmacyclics anticipates an update on this program will be provided during the first half of 2014.
  • Conference CallThe Company will hold a conference call today at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-303-7908 for domestic callers and 1-678-373-0875 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. To access a replay of the call please dial 1-855-859-2056 domestic callers and 1-404-537-3406 for international callers and use the conference ID number: 23863642.  The archived version of the webcast and conference call will be available for 30 days on the Investor Relations section of the Company's Web site at http://www.pharmacyclics.com.

    About IbrutinibIbrutinib is an investigational agent designed to provide potent and sustained inhibition of an enzyme called Bruton's tyrosine kinase (BTK). By inhibiting BTK, ibrutinib blocks B-cell receptor signaling. BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... July 23, 2014  Researchers from the North American ... elevates calcium levels too high, 1 putting ... problems. Women close to menopause are commonly ... to prevent diseases such as osteoporosis, to which they ... women determine how much calcium they typically get through ...
    (Date:7/23/2014)... This September leading clinicians in orthodontics and ... for DOCtalk 2014 —a "Dynamic Orthodontic ... and private practitioner Dr. David Sarver , DOCtalk ... clinical and practice management efficiency and high quality patient ... to welcome fresh thinking and join a community of ...
    (Date:7/23/2014)... , July 23 2014 Ampio Pharmaceuticals, ... its new headquarters, manufacturing and research facility: ... 80112 Direct: (720) 437-6500 ... efficient, pharmaceutical drug manufacturing facility will be fully operational ... the first batches of Ampion TM necessary to ...
    Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
    ... 2011 Assured Pharmacy (Pink Sheets: APHY ), ... than 3,000 sufferers of chronic pain announced that total sales ... 2010 were $1,514,984 which equates to $70,464 per business day. ... total sales of $1,348,344 for December 2009 which equates to ...
    ... 2011 BioDelivery Sciences International, Inc. ... outcome of a pre-Investigational New Drug (pre-IND) meeting ... on the development program for BEMA Buprenorphine/Naloxone, BDSI,s ... discussed is based on pharmacokinetic and safety data ...
    Cached Medicine Technology:Assured Pharmacy Reports Same Store Sales for the Month of December 2010 2Assured Pharmacy Reports Same Store Sales for the Month of December 2010 3BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 2BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 3
    (Date:7/23/2014)... 2014 The European Vitamins Market report ... analysis and projection of revenue. The market in Europe ... 2012 to $1,202.08 million by 2018, at a CAGR ... the TOC of the European Vitamins Market report, to ... also provides a glimpse of the segmentation in the ...
    (Date:7/23/2014)... RFcnn.com, a distinguished electrical equipment retailer, has ... . What’s more, the company has decided to provide big ... who place an order for the company’s brand new SMA ... , The high quality SMA JACK from RFcnn.com Provides ... superb quality electrical equipment to help make things much easier ...
    (Date:7/23/2014)... 23, 2014 "I wanted a better way ... as my blood sugar, blood pressure and pulse rate," said ... to have to carry along a bunch of different devices, ... He developed the Master III to make it easier to ... one convenient unit. The accessory enables the user to have ...
    (Date:7/23/2014)... hued dyes, George Mason University researchers discovered an ... other, possibly leading to new treatments for cancer, ... George Mason researchers unraveled the mystery of deciphering ... "One protein interlocks with another protein like adjacent ... a signal down the line to the next ...
    (Date:7/23/2014)... According to a new market research report of ... IP, SOC IP), Design Architecture (Hard IP, Soft IP), ... - Forecast & Analysis to 2013 - 2020", the ... a CAGR of 12.6% from 2014 to 2020 and ... 76 market data tables with 60 figures spread through ...
    Breaking Medicine News(10 mins):Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:New Collection of SMA JACK Released by China Electrical Accessory Manufacturer RFcnn 2Health News:Researchers unlock the protein puzzle 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6
    ... who receive higher disability ratings for work-related back injuries ... those who get lower ratings.// ,This ... relationship between Workers’ Compensation settlements for back pain and ... showing ‘blacks receive less treatment for their back pain ...
    ... Researchers at Mayo Clinic have successfully isolated nanoparticles from ... RNA and DNA that appear to be associated with ... December issue of the Journal of Investigative Medicine, are ... the mystery of whether nanoparticles are viable living forms ...
    ... have a genetic predisposition. //This study is lead by ... helix. ,Collaborated Research is being launched by Researchers ... Institute for Medical Research and Cold Spring Harbor Laboratory ... ,"For complex illnesses like bipolar disorder that vary dramatically ...
    ... but a medical aberration until recently—are now becoming a ... that has pediatricians at the Johns Hopkins Children’s Center, ... doctors have yet to quantify the precise increase and ... play some role—pediatricians agree that too much salt and ...
    ... welcomed the first formal agreement to deliver a fast, ... move as a win for patients and doctors alike. ... first organisation to sign up to deliver the new ... immediately after paying the doctor’s bill. ,The ...
    ... woman succumbed to bird flu.// With this, the total number of ... since March 2006. ,The woman aged 30 years had ... detected with H5N1 barely a few hours before she died. Though ... since mid- December, Doctors had not checked her out for ...
    Cached Medicine News:Health News:Is Workers’ Comp. Settlements for Back Pain Fair 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3Health News:Research on Bipolar Disorder Launched 2Health News:Kidney Stones Occurring More Often in Children 2